{
    "nctId": "NCT00847366",
    "briefTitle": "Open Label Trial of Perifosine in Patients Currently Being Treated on Perifosine Trials in Solid Tumors or Multiple Myeloma",
    "officialTitle": "An Open Label Trial of Perifosine in Patients Currently Being Treated on Perifosine Trials in Solid Tumors or Multiple Myeloma",
    "overallStatus": "COMPLETED",
    "conditions": "Non Small Cell Lung Cancer, Solid Tumors, Metastatic Breast Cancer, Sarcomas",
    "studyType": "INTERVENTIONAL",
    "phase": "NA",
    "allocation": "NON_RANDOMIZED",
    "primaryPurpose": "TREATMENT",
    "enrollmentCount": 10,
    "primaryOutcomeMeasure": "To evaluate the safety and tolerability",
    "eligibilityCriteria": "Inclusion Criteria:\n\n* Patients must be currently receiving treatment with perifosine on a previously approved protocol.\n* Patients must have had at least one evaluation following the initiation of treatment and have stable disease, partial response or complete response.\n* Patient is willing to sign a new consent Regarding the protocol no exclusion criteria are described.",
    "sex": "ALL",
    "minimumAge": "18 Years",
    "stdAges": "ADULT, OLDER_ADULT"
}